BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.

Trial Details

NCT ID
NCT06793449
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • anti-BCMA CAR-T
  • ASCT
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Be informed and voluntarily sign the Informed Consent Form (ICF).
  • Age between 18 and 70 years (inclusive).
  • Have measurable disease meeting at least one of the following criteria: Serum M-protein ≥1 g/dL (\>10 g/L) as detected by serum protein electrophor…
  • Confirmed expression of the BCMA target antigen on MM cells by flow cytometry or bone marrow immunohistochemistry.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →